In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Becomes the first rehab & recovery center in east India to earn NABH accreditation
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
This project is supported by the Irish Government through IDA Ireland
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
Subscribe To Our Newsletter & Stay Updated
